Global Cough Suppressant Drugs Market Overview
Cough is reflex action that clears throat of mucus and is a common symptom of various respiratory tract infections. Cough suppressant drugs, are widely used in order to relieve symptoms of cough. Cough suppressant drugs primarily reduces activity of cough reflex as well as suppresses urge to cough. Cough suppressant drugs that are commonly used in the treatment of cough are Codeine and Dextromethorphan.
Increasing prevalence of cough, coupled with frequent launches of new cough suppressant drugs are major factors driving growth of the cough suppressant drugs market. In addition, increasing approvals to the novel drugs by regulatory bodies across the globe is another factor expected to propel growth of the global market in the near future. Furthermore, increasing initiatives by major players operating in the target market to evaluate safe and efficient drug for the treatment of cough is a factor supporting growth of the global market.
The cough suppressant drugs market has been segmented on the basis of disease type, drug type, product type, age group, dosage form, distribution channel, and region.
The disease type segment includes dry cough and wet cough. On the basis of drug type segment the target market has been segmented as dextromethorphan, codeine, noscapine, butamirate, benzonatate, and pholcodine. On the basis of product type the global market has been segmented as over-the-counter and prescription drug. On the basis of age group the cough suppressant drugs market has been segmented as pediatric and adult. The dosage form segment includes syrup and tablet. On the basis of distribution channel the global market has been segmented as hospital, retail pharmacy, online pharmacy, and others.
On the basis of region the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions. This can be attributed to frequent approvals to novel drugs by the Food and Drug Administration in the countries of the region especially in the U.S. and Canada.
Key players operating in the cough suppressant drugs market includes Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.
Global Cough Suppressant Drugs Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- PORTER’s
- Investment Outlook
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Cough Suppressant Drugs Strategies
- Key Questions this Study will Answer
-
By Disease Type (Dry Cough and Wet Cough)
By Drug Type (Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, and Pholcodine)
By Product Type (Over-the-counter and Prescription Drug)
By Age Group (Pediatric and Adult), By Dosage Form (Syrup and Tablet)
By Distribution Channel (Hospital, Retail Pharmacy, Online Pharmacy, and Others)
By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Regional Analysis
- Regional Revenue Analysis
- Regional By segment Analysis
- Reasons for regional growth
- Key Player of particular region
- Countries Include in the report:
-
-
- North America (U.S., Canada)
- Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
- Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
- Latin America (Brazil, Mexico, Rest of Latin America)
- Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)
-
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Competitive Overview
- Competitive Benchmarking
- Market Share Analysis
- Key Developments In The Global Cough Suppressant Drugs Market
- Key Developments: Mergers & Acquisitions
- Key Developments: Collaboration
- Key Developments: Contracts & Agreements
- Key Developments: Expansion
- Key Developments: Product Developments
- Company Profiles
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- SWOT Analysis
-
-
Perrigo Company plc
-
Vernalis plc
-
Tris Pharma Inc.
-
Pfizer Inc.
-
Aytu BioScience, Inc.
-
Acella Pharmaceuticals LLC
-
Mayne Pharma Inc.
-
Taro Pharmaceutical Industries Ltd.
-
Amneal Pharmaceuticals LLC
-
Aurobindo Pharma Ltd
-
GlaxoSmithKline plc
-
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The cough suppressant drugs market has been segmented on the basis of disease type, drug type, product type, age group, dosage form, distribution channel, and region.
Emerging trends include the development of combination therapies, the focus on natural and herbal cough suppressants, and advancements in formulation technologies for improved efficacy and patient compliance. Opportunities arise from the increasing prevalence of respiratory conditions leading to cough, the demand for non-drowsy formulations, and the exploration of over-the-counter (OTC) options.
Key factors include the persistent prevalence of respiratory infections, exposure to environmental irritants, lifestyle factors contributing to chronic cough, and the demand for effective relief from cough symptoms. Additionally, advancements in drug delivery systems, patient preferences for over-the-counter solutions, and the potential for targeted therapies contribute to market growth.
Regions covered include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the market due to a well-established healthcare infrastructure, high prevalence of respiratory conditions, and significant consumer awareness. However, the Asia-Pacific region is experiencing notable growth, driven by increasing healthcare awareness, a large population with respiratory conditions, and the expansion of pharmaceutical markets in countries like China and India.
Key players operating in the cough suppressant drugs market includes Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.